Actelion Chooses GENEART as Exclusive Supplier for DNA Engineering & Processing Services

Framework agreement with Actelion Pharmaceuticals Ltd. signed

08-Jul-2009 - Germany

GENEART AG announces the signing of a framework agreement with the Swiss company Actelion Pharmaceuticals Ltd. Within the scope of this agreement, Actelion will receive system solutions for DNA engineering & processing (gene optimization, gene synthesis and plasmid preparation) exclusively from GENEART from now on. Further contract terms were not disclosed. The contract does not restrict GENEART in supplying service solutions for other customers.

"Gene optimization and gene synthesis offer many advantages over conventional methods in molecular biology. For instance, genes can be tailored to the respective customer project by our GeneOptimizer® software without any restrictions and subsequently produced within a few days. This not only shortens development times for biopharmaceuticals, but also increases the yield and thus reduces production and project costs. The fully DIN EN ISO 9001:2000 certified processes of GENEART and the world-wide highest production capacities additionally ensure reliable and quick processing of customer projects with observance of the required quality standards for the development of pharmaceutical agents", Prof. Dr. Ralf Wagner, CEO of GENEART AG, explains.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances